| Drug Name: | Amsacrine (51264-14-3) |
|---|---|
| PubChem ID: | 2179 |
| SMILES: | COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42 |
| InchiKey: | XCPGHVQEEXUHNC-UHFFFAOYSA-N |
| Therapeutic Category: | Antineoplastic Agents, Indicators and Reagents, Intercalating Agents |
| Molecular Weight (dalton) | : | 393.468 |
| LogP | : | 4.5117 |
| Ring Count | : | 4 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 80.32 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Dna Degradation | DNA topoisomerase 1 (P11387) | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes through the pathway of rapidly triggered DNA degradation in S phase [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category